rodent model
Recently Published Documents


TOTAL DOCUMENTS

2501
(FIVE YEARS 489)

H-INDEX

76
(FIVE YEARS 8)

Author(s):  
Muneerah I. AL tamimi ◽  
Hanan A. Alfawaz ◽  
Ramesa Shafi Bhat ◽  
Shaista Arzoo ◽  
Dina A. Soliman ◽  
...  

2022 ◽  
pp. 1-9
Author(s):  
Kotaro Hori ◽  
Tadashi Matsuura ◽  
Shogo Tsujikawa ◽  
Hideki Hino ◽  
Miyuki Kuno ◽  
...  

2022 ◽  
Vol 137 ◽  
pp. 105087
Author(s):  
Bianca Santos Martins Gonçalves ◽  
Flora França Nogueira Mariotti ◽  
Giovana Ponsone ◽  
Thalita Aparecida Avelino Soares ◽  
Paula Cristina Barbosa Garcia Perão ◽  
...  

2022 ◽  
Vol 226 (1) ◽  
pp. S311
Author(s):  
Ron Beloosesky ◽  
Sally Rashid ◽  
Idit Golani ◽  
Alon Rubinstein ◽  
Ravid doron ◽  
...  

Author(s):  
Kavitha Andugula ◽  
Narendra Babu Ankem

Current animal models of infertility in female rats fail to adequately recapitulate transitions like fluctuations in hormonal changes and other complications. androgen-induced infertility rodent model is cause PCO and a new rodent model of Accelerated ovarian failure (AOF) successfully replicate the human perimenopause and postmenopause also it including estrus acyclicity and undetectable estrogen levels .This models not only for menopause it is also useful method for various other infertility models, to develop this model various chemicals are used but in that all models 4- Vinyl cyclohexene diepoxide (VCD) novel chemical which is used for induction of menopause in female rodents. Along with menopause it can also used for other infertility and gynecological complications. In this study other infertility models were compared with androgen induced infertility rodent model, VCD model and our aim to use this animal models to elucidate novel perspective and interventions for maintaining a high quality of life in women and to potentially decrease the negative health consequences associated with these changes during age and other gynecological, neurological complications.


2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Takayuki Kondo ◽  
Stewart Macdonald ◽  
Cornelius Engelmann ◽  
Abeba Habtesion ◽  
Jane Macnaughtan ◽  
...  

AbstractAcute-on-chronic liver failure (ACLF) is characterized predominantly by non-apoptotic forms of hepatocyte cell death. Necroptosis is a form of programmed lytic cell death in which receptor interacting protein kinase (RIPK) 1, RIPK3 and phosphorylated mixed lineage kinase domain-like (pMLKL) are key components. This study was performed to determine the role of RIPK1 mediated cell death in ACLF. RIPK3 plasma levels and hepatic expression of RIPK1, RIPK3, and pMLKL were measured in healthy volunteers, stable patients with cirrhosis, and in hospitalized cirrhotic patients with acutely decompensated cirrhosis, with and without ACLF (AD). The role of necroptosis in ACLF was studied in two animal models of ACLF using inhibitors of RIPK1, necrostatin-1 (NEC-1) and SML2100 (RIPA56). Plasma RIPK3 levels predicted the risk of 28- and 90-day mortality (AUROC, 0.653 (95%CI 0.530–0.776), 0.696 (95%CI 0.593–0.799)] and also the progression of patients from no ACLF to ACLF [0.744 (95%CI 0.593–0.895)] and the results were validated in a 2nd patient cohort. This pattern was replicated in a rodent model of ACLF that was induced by administration of lipopolysaccharide (LPS) to bile-duct ligated rats and carbon tetrachloride-induced fibrosis mice administered galactosamine (CCL4/GalN). Suppression of caspase-8 activity in ACLF rodent model was observed suggesting a switch from caspase-dependent cell death to necroptosis. NEC-1 treatment prior to administration of LPS significantly reduced the severity of ACLF manifested by reduced liver, kidney, and brain injury mirrored by reduced hepatic and renal cell death. Similar hepato-protective effects were observed with RIPA56 in a murine model of ACLF induced by CCL4/GalN. These data demonstrate for the first time the importance of RIPK1 mediated cell death in human and rodent ACLF. Inhibition of RIPK1 is a potential novel therapeutic approach to prevent progression of susceptible patients from no ACLF to ACLF.


2021 ◽  
Vol 14 ◽  
Author(s):  
James I. Jones ◽  
Christopher J. Costa ◽  
Caitlin Cooney ◽  
David C. Goldberg ◽  
Matthew Ponticiello ◽  
...  

Most diabetes patients eventually suffer from peripheral nerve degeneration. Unfortunately, there is no treatment for the condition and its mechanisms are not well understood. There is, however, an emerging consensus that the inability of peripheral nerves to regenerate normally after injury contributes to the pathophysiology. We have previously shown that regeneration of peripheral axons requires local axonal translation of a pool of axonal mRNAs and that the levels and members of this axonal mRNA pool are altered in response to injury. Here, we show that following sciatic nerve injury in a streptozotocin rodent model of type I diabetes, this mobilization of RNAs into the injured axons is attenuated and correlates with decreased axonal regeneration. This failure of axonal RNA localization results from decreased levels of the RNA binding protein ZBP1. Over-expression of ZBP1 rescues the in vitro growth defect in injured dorsal root ganglion neurons from diabetic rodents. These results provide evidence that decreased neuronal responsiveness to injury in diabetes is due to a decreased ability to alter the pool of axonal mRNAs available for local translation, and may open new therapeutic opportunities for diabetic peripheral neuropathy.


2021 ◽  
Vol 177 ◽  
pp. S65
Author(s):  
Cátia F. Lourenço ◽  
João Gonçalves ◽  
José Sereno ◽  
Miguel Castelo-Branco ◽  
João Laranjinha

Sign in / Sign up

Export Citation Format

Share Document